Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 606

1.

Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.

Chan EW, Lau WC, Siu CW, Lip GY, Leung WK, Anand S, Man KK, Wong IC.

Heart Rhythm. 2016 Mar 28. pii: S1547-5271(16)30150-3. doi: 10.1016/j.hrthm.2016.03.049. [Epub ahead of print]

PMID:
27033342
2.

The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.

Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K.

Pathology. 2016 Jan;48(1):60-71. doi: 10.1016/j.pathol.2015.11.025. Epub 2015 Dec 17.

PMID:
27020211
3.

Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation - Results of the J-RHYTHM Registry 2.

Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators.

Circ J. 2016 Mar 25;80(4):843-51. doi: 10.1253/circj.CJ-16-0066. Epub 2016 Mar 18.

4.

Periprocedural Management of Patients on a Vitamin K Antagonist or a Direct Oral Anticoagulant Requiring an Elective Procedure or Surgery.

Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD.

J Thromb Haemost. 2016 Mar 14. doi: 10.1111/jth.13305. [Epub ahead of print] Review.

PMID:
26988871
5.

The Use of Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients with History of Intra-Cranial Hemorrhage.

Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA.

Circulation. 2016 Mar 11. pii: CIRCULATIONAHA.115.019794. [Epub ahead of print]

PMID:
26969761
6.

Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study.

Mochalina N, Jöud A, Carlsson M, Sandberg ME, Själander A, Juhlin T, Svensson PJ.

Thromb Res. 2016 Apr;140:94-9. doi: 10.1016/j.thromres.2016.02.023. Epub 2016 Feb 23.

PMID:
26938155
7.

Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.

Arihiro S, Todo K, Koga M, Furui E, Kinoshita N, Kimura K, Yamagami H, Terasaki T, Yoshimura S, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S, Okada Y, Nagakane Y, Kameda T, Hasegawa Y, Shibuya S, Ito Y, Nakashima T, Takamatsu K, Nishiyama K, Matsuki T, Homma K, Takasugi J, Tokunaga K, Sato S, Kario K, Kitazono T, Toyoda K; SAMURAI Study Investigators.

Int J Stroke. 2016 Feb 29. pii: 1747493016632239. [Epub ahead of print]

PMID:
26927811
8.

Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.

Alcocer L.

Am J Cardiovasc Drugs. 2016 Feb 29. [Epub ahead of print]

PMID:
26923792
9.

Individualized approaches to thromboprophylaxis in atrial fibrillation.

Ziff OJ, Camm AJ.

Am Heart J. 2016 Mar;173:143-58. doi: 10.1016/j.ahj.2015.10.021. Epub 2015 Nov 11. Review.

PMID:
26920607
10.

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.

Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, Gersh BJ, Shah ND, Noseworthy PA.

J Am Heart Assoc. 2016 Feb 23;5(2). pii: e003074. doi: 10.1161/JAHA.115.003074.

11.

Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study.

Vestergaard AS, Skjøth F, Lip GY, Larsen TB.

Stroke. 2016 Apr;47(4):979-85. doi: 10.1161/STROKEAHA.115.012338. Epub 2016 Feb 16.

PMID:
26883499
12.

NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis.

Hicks T, Stewart F, Eisinga A.

Open Heart. 2016 Jan 18;3(1):e000279. doi: 10.1136/openhrt-2015-000279. eCollection 2016.

13.

Asian strategy for stroke prevention in atrial fibrillation.

Chiang CE, Wang KL, Lin SJ.

Europace. 2015 Oct;17 Suppl 2:ii31-ii39. doi: 10.1093/europace/euv231. Review.

PMID:
26842113
14.

[Management of bleeding complications associated with NOAC].

von Ameln-Mayerhofer A.

Med Monatsschr Pharm. 2015 Oct;38(10):389-93. German.

PMID:
26731856
15.

[The role of new oral anticoagulants in cerebrovascular diseases].

Orosz P.

Neuropsychopharmacol Hung. 2015 Dec;17(4):183-90. Review. Hungarian.

16.

Matching the NOAC to the Patient: Remember the Modifiable Bleeding Risk Factors.

Lip GY, Lane DA.

J Am Coll Cardiol. 2015 Dec 1;66(21):2282-4. doi: 10.1016/j.jacc.2015.07.086. No abstract available.

PMID:
26610875
17.

Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.

Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, Becker RC, Singer DE, Halperin JL, Hankey GJ, Berkowitz SD, Fox KA, Patel MR.

J Am Coll Cardiol. 2015 Dec 1;66(21):2271-81. doi: 10.1016/j.jacc.2015.09.024.

18.
19.

Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.

Sarma A, Giugliano RP.

Hosp Pract (1995). 2015;43(5):258-67. doi: 10.1080/21548331.2015.1103190. Epub 2015 Nov 11. Review.

PMID:
26559852
20.

[Novel oral anticoagulants (NOAC)].

Ieko M.

Rinsho Ketsueki. 2015 Oct;56(10):2123-33. doi: 10.11406/rinketsu.56.2123. Japanese.

PMID:
26458452
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk